Objective: We conducted a retrospective analysis to evaluate the efficacy and safety of cetuximab plus radiation with or without prophylactic PEG in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) patients who were not suitable to receive platinum. Results: The incidence of leukopenia was significantly higher in patients without PEG placement than in those with (67.5 % vs. 7%, p=0.002). The incidence of grade 3 or 4 mucositis tended to be higher in patients without PEG placement than in those with (83% vs.47%, p=0.058). Five of 12 patients without PEG placement required interruption of treatment. More patients without PEG placement had significantly 4 greater than 10% weight loss than patients with (75% vs 27%, p=0.013). The overall response rate was 56% in all patients. The 1-year progression-free survival (PFS) rate was 30.6% in all patients.
Introduction
The standard treatment for unresectable locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) is platinum-based chemoradiotherapy (CRT) (1) (2) . A standard regimen of CRT is high-dose cisplatin (CDDP 100 mg/m 2 on day1, 22, 43) plus RT. However(3), high cisplatin is not suitable for patients with certain risk factors, including old age, kidney and/or cardiac dysfunction, brain infarction and hearing loss.
In the Bonner trial, a pivotal prospective randomized phase III trial which compared radiation with or without cetuximab for LA-SCCHN, the addition of cetuximab to radiotherapy significantly improved locoregional control, progression-free survival, and overall survival without increasing the incidence of radiation-related toxicities, including mucositis and dysphagia (4) (5). Although no direct comparison with CRT has appeared, cetuximab plus radiation is an alternative treatment option in LA-SCCHN.
A phase II study to confirm the feasibility of cetuximab plus radiotherapy for locally advanced head and neck cancer in Japanese patients (6) reported similar tolerability and efficacy with those reported in the Bonner trial, leading to the approval of cetuximab for head and neck cancer in Japan. However, the incidence of grade 3 or worse mucosal inflammation was somewhat higher than that reported for mucositis in the cetuximab plus radiotherapy arm of the Bonner trial (73% vs 56%).
Investigators in the Bonner trial could select one of three radiotherapy-fractionation regimens -single daily, twice daily and concomitant boost. In the Japanese feasibility trial, in contrast, only concomitant boost radiotherapy was allowed when combined with cetuximab. Further, patients treated with concomitant boost in the Bonner trial experienced more high-grade mucositis than with standard fractionation (7). We therefore concluded that the higher incidence of mucositis in the Japanese trial was because of its use of concomitant boost radiotherapy only. Furthermore, we speculated that the addition of cetuximab to single daily radiotherapy for Japanese patients would not increase radiation-related toxicities, as in the Bonner trial. Therefore, we initially did not perform prophylactic percutaneous endoscopic gastrectomy (PEG) in patients who received cetuximab plus radiation, as is also not done in patients receiving radiation alone in our institution. However, most patients developed severe mucositis, dysphagia and radiation dermatitis, leading to treatment interruption. To avoid treatment interruption, prophylactic PEG placement is mandatory for patients with locally advanced head and neck cancer who receive concurrent CRT in our institute. The previous studies demonstrated that treatment interruption were associated with increased local relapse, and worsening of local control (8). Accordingly, our institution mandated prophylactic PEG placement before the start of cetuximab plus radiation.
However, the efficacy and safety of cetuximab plus radiation with or without prophylactic PEG in LA-SCCHN patients who are not suitable to receive platinum is unknown.
Here, we conducted a retrospective analysis to evaluate the tolerability of cetuximab plus radiation therapy for the LA-SCCHN patients with or without prophylactic PEG placement.
Patients and methods
We retrospectively reviewed the medical records of 27 patients with locally advanced SCCHN treated with radiotherapy in combination with cetuximab for head and neck cancer at the National Cancer Center Hospital East between January 2013 and July 2014.
All patients were unable to receive cisplatin due to cardiac and kidney dysfunction, old age, and complications (poorly controlled diabetes, and alcoholic liver cirrhosis). Survival curves were generated using the Kaplan-Meier method. Safety and efficacy analyses were conducted on an intention-to-treat basis, defined as all patients who received at least one dose of cetuximab. Progression-free survival (PFS) was calculated from the date of the first administration of chemotherapy to the first documentation of disease progression, subsequent therapy (for example, salvage operation and chemotherapy), or death. Overall survival (OS) was determined from the date of the first administration of chemotherapy to the date of death or the last confirmed date of survival. Chi-square test, analysis of variance, and log-rank test were used for analysis.
Statistical data were obtained using the SPSS software package (SPSS statistics 21®, SPSS Inc. Chicago IL, USA).
Results

Patient Characteristics
Patient characteristics are summarized in Table 1 . Treatment details are described in Table 2 . Fifteen patients received prophylactic PEG placement before cetuximab plus radiation while twelve patients did not. Reasons for administration of cetuximab were age > 75 years, renal dysfunction, and complications including poor control of diabetes mellitus, cardiovascular disease and cirrhosis. There was no significant difference in patient characteristics between those receiving and not receiving PEG placement.
Adverse Events
There were no adverse events related with prophylactic PEG replacement. Hematologic and non-hematologic toxicities are listed in Table 3 . Among hematological toxicities, the incidence of leukopenia was significantly higher in patients without PEG placement than in those with (67.5% vs. 7%, p=0.002). The incidence of grade 3 or 4 anemia (grade 3 to 5) tended to be higher in those without PEG placement (p=0.188). In contrast, the incidence of neutropenia, thrombocytopenia and hypomagnesemia (all grades) in the two groups was similar.
The most common non-hematological toxicities were mucositis and radiation dermatitis. The incidence of grade 3 or 4 mucositis tended toward be higher in patients without PEG placement (83% vs.47%, p=0.058). All patients received both mucosal care and education about gargling by a dentist, indicating that there was no difference in compliance with mucosal care between the two groups. No difference in the incidence of other non-hematological toxicities was observed. No deaths due to treatment-related adverse events were seen.
Although all patients completed radiotherapy, five of 12 patients without PEG placement required interruption of treatment due to infected mucositis (three patients) and infection of the inserted central venous catheter (two patients) ( Table 2 ). The median RT interruption was 4 (range 3-5) days.
Seventeen of 27 patients (63%) were required emergency hospitalization. Of these, eight had received prophylactic PEG and nine had not. The difference did not reach statistical significance (p=0.226). The most common reasons for emergency hospitalization were worsening nutrition, including due to the non-use of PEG, and infection due to mucositis. Most of these patients could not receive family support because they lived alone.
Clinical weight loss ≥ 10% during treatment was observed in 13 patients (48%).
Incidence was higher in patients without PEG placement (75% vs. 27%, p=0.013).
Further, the mean and percent rate reductions in body weight tended to be higher in those without PEG placement (5.5 kg vs 4.9kg (8.8 % vs 9.6%)) ( Table 5 ).
Median duration of PEG placement was 10.3 months (range 5.2-15.3 months). Seven of 15 patients (46.6%) underwent removal within 1 year, while removal within 1 year was not possible in 8 patients due to persistent primary tumor (n=4) and dysphagia as a result of pharyngeal stenosis (n=4) Median follow-up time was 13 months (range 6.0 -22.0 months). Overall response rate by RECIST was 56% in all patients. The 1-year PFS, locoregional control rate, and OS in all patients were 30.6%, 30.2%, and 89.7%, respectively (Figure 1 ). The 1-year PFS and locoregional control rates for diseases of the oropharynx were 43.6%, 43.6%, and 25.0% and 28.1% for disease of the hypopharynx and larynx. The 1-year PFS of current smokers compared with former/never smokers was 24.7% and 45.0%, respectively. The 1-year PFS in the prophylactic PEG placement group compared with the PEG no placement group was 33.3% and 33.3%, respectively (p=0.934). The 1-year OS of prophylactic PEG placement group compared with the PEG no placement group was 93.3% and 73.3%, respectively (p=0.055) (Fig 2, Fig 3) . PFS and OS were not significantly different in patients without RT interruption, but tended to be better than in patients with RT interruption, albeit that the study population was small (1 year PFS, 31.8% versus 40%, p=0.606; 1 year OS, 90.5% versus 60%, p=0.362, respectively) Local relapse developed in 13 patients (five with oropharyngeal disease, six patients with hypopharyngeal, and two patients with laryngeal disease). Regional relapse as lymph node recurrence or skin metastasis in the radiation field developed in four patients with hypopharyngeal and one patient with laryngeal disease. One patient had local and regional relapse. One patient developed distant metastasis to the lung. Eight patients underwent salvage surgery, included total pharyngo-laryngo-esophagectomy in six, neck dissection (ND) in one, and total laryngectomy plus ND in one. Five patients subsequently received palliative chemotherapy, while five received best supportive care.
Discussion
Optimal management of toxicities during cetuximab plus RT has not been established.
Our retrospective study of patients receiving cetuximab plus RT demonstrated that prophylactic PEG placement reduced the incidence of severe toxicities, including mucositis and weight loss, leading to the avoidance of RT interruption, which has been associated with increased local relapse and worsening of local control (8) (12) .
Previous studies have demonstrated that malnutrition is associated with the increased severity of CRT-related toxicities, which in turn lead to treatment interruption (13) (14) (15) (16) . Appropriate nutrition control during definitive therapy is therefore essential for avoiding RT interruption.
Folllowing the results of Bonner' study, the addition of cetuximab has demonstrated significant improvement in both locoregional control and overall survival without worsening RT-related toxicities. However, several studies demonstrated that the incidence of RT-related toxicities was the same as that of CRT (17) (18) Cetuximab plus radiation is widely used as an alternative to CRT for the patients who are not candidates for CDDP due to adverse organ function, such as renal dysfunction and comorbidities. These patients are at increased risk of toxicities than those who are fit to receive cisplatin. In fact, our experience revealed that the patients who did not undergo PEG placement developed severe mucositis and dysphagia, which lead to the interruption of RT radiation. Furthermore, they require nutrition from a central venous catheter during therapy, and several patients required it for several months after therapy, leading to increased risk of catherter-related infection due to skin colonization at the insertion site and the patient and hospital environment (21) (22).
Complications with a nasogastric tube include nasal irritation, mucosal ulceration, and aspiration pneumonia (23) . These risks are reduced with PEG (24) (25) (26). Weight >10% loss during CRT is reported to reduce OS, PFS, performance status, and physical function with statistical significance (27). Early nutrition and the benefits of PEG placement have been reported, such as decreased weight loss, decreased hospitalization for nutrition or dehydration issues, and fewer treatment interruptions (28) (29). Enteral feeding through a pre-CRT-placed PEG is effective and safe (30) (31). Major complications related to the use of PEG by the direct method, such as pan-or localized peritonitis and bleeding. Of the 421 patients who underwent PEG by the direct method in our institute, 9 (2.1%) developed peritonitis related to the PEG procedure. One patient with terminal stage lung cancer who needed PEG for palliative care required emergency surgical drainage while the remaining 8 recovered with conservative treatment, indicating that this method has an extremely low risk of adverse effects on treatment for locally advanced SCCHN (32) . In fact, there was no adverse event related to prophylactic PEG placement Although the relative benefits of prophylactic versus therapeutic PEG-feeding tube placement are controversial, we are convinced that prophylactic placement is indispensable to the completion of these high-intensity treatments. In fact, after prophylactic placement of PEG, all patients receiving cetuximab plus RT could complete their treatment without treatment interruption.
The impact of prophylactical PEG use on swallowing-related outcomes remains unclear. We therefore recommend that patients continue to take meals orally and undergo dysphagia rehabilitation during cetuximab plus radiation and CRT. If patients achieve CR and can take food orally after treatment, we recommend removing the PEG as soon as possible.
The incidence of leukopenia was significantly higher in patients without PEG placement than in those with PEG. Some articles have reported that malnutrition is associated with lymphopenia, anemia and weight loss (33) (34) . Protein malnutrition decreases the production of blood cells, leading to bone marrow hypoplasia and inducing structural alterations which interfere with both innate and adaptive immunity.
We hypothesized that malnutrition was associated with myelosuppression and immunosuppression, leading to the worsening of leukopenia and anemia.
Multiple scores are available for evaluating the nutritional status of cancer patients. Prealbumin is used to monitor acute changes in the nutritional status of patients.
Results may be influenced by the presence of infection and inflammation, however. For our present study population, a higher incidence of severe mucositis and dermatitis were observed, indicating that prealbumin is inappropriate for the evaluation of nutritional status.
Both response rate and PFS in the current study were lower than that in Bonner trial (response rate, 56% vs. 74%; 1 year PFS, 8.3 vs 17.1 months, respectively). The percentage of patients with oropharyngeal cancer was smaller in our present study than in the Bonner trial. Furthermore, all patients in the current study were unsuitable for platinum due to their older age ( > 75 years), renal dysfunction and severe complications, leading to the poor outcomes compared with previous studies.
The present study has several limitations, including the small number of study subjects and retrospective study design.
In conclusion, our analysis reveals that prophylactic PEG-feeding tube placement reduces the incidence of severe toxicities, including mucositis and weight loss, and thereby helps avoiding RT interruption. Additional larger studies are required to confirm these results. Completed without interruption 15 7
Completed with interruption* 0 5
Reasons for interruption of radiation Mucosal infection, Grade 3 0 3
Central catheter-related infection, Grade 3 0 2 *: Long interval due to a national holiday. 
